Scholarlink

<p>The therapeutic landscape of hematological malignancies has been transformed by targeted therapies, immunotherapy, and cellular therapies, leading to more complex and prolonged clinical courses. Currently, there is substantial variability in how “lines of therapy” (LoT) are defined and recorded, which hinders research and data harmonization. To address this, the EBMT Practice Harmonisation and Guidelines Committee has developed a standardized framework for LoT across acute leukemias, lymphomas, and multiple myeloma. A LoT is defined as a coherent therapeutic episode aimed at achieving or maintaining disease control, comprising one or more systemic treatment phases such as induction, consolidation, or maintenance, administered in the absence of disease progression, treatment failure, or major toxicity. A new LoT is assigned at documented progression, relapse, or primary refractory disease, and the introduction of an agent from a distinct therapeutic class to deepen response also constitutes a new line, whereas dose adjustments, schedule changes, or planned omissions to manage toxicity do not create a new LoT. Bridging therapies administered prior to cellular therapy, including CAR-T or transplantation, are considered part of the same LoT as the definitive treatment. This initiative aims to enhance methodological rigor, improve clarity in treatment reporting, and support evidence-based decision-making in precision hematology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Defining lines of therapy in haematological malignancies: a proposed systematic and comprehensive framework from the EBMT Practice Harmonisation and Guidelines Committee

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月3日

查看全文
  • Alessandro Criscimanna,
  • Jacques-Emanuel Galimard,
  • Isabel Sánchez-Ortega,
  • Patrick J. Hayden,
  • Laurent Garderet,
  • Anna Sureda,
  • Fabio Ciceri,
  • Donal P. McLornan,
  • Krzysztof Kałwak,
  • Antonio M. Risitano,
  • Francesco Onida,
  • Ibrahim Yakoub-Agha,
  • Ali Bazarbachi,
  • Annalisa Ruggeri

摘要

The therapeutic landscape of hematological malignancies has been transformed by targeted therapies, immunotherapy, and cellular therapies, leading to more complex and prolonged clinical courses. Currently, there is substantial variability in how “lines of therapy” (LoT) are defined and recorded, which hinders research and data harmonization. To address this, the EBMT Practice Harmonisation and Guidelines Committee has developed a standardized framework for LoT across acute leukemias, lymphomas, and multiple myeloma. A LoT is defined as a coherent therapeutic episode aimed at achieving or maintaining disease control, comprising one or more systemic treatment phases such as induction, consolidation, or maintenance, administered in the absence of disease progression, treatment failure, or major toxicity. A new LoT is assigned at documented progression, relapse, or primary refractory disease, and the introduction of an agent from a distinct therapeutic class to deepen response also constitutes a new line, whereas dose adjustments, schedule changes, or planned omissions to manage toxicity do not create a new LoT. Bridging therapies administered prior to cellular therapy, including CAR-T or transplantation, are considered part of the same LoT as the definitive treatment. This initiative aims to enhance methodological rigor, improve clarity in treatment reporting, and support evidence-based decision-making in precision hematology.